All Enterobacteriaceae express a polysaccharide known as Enterobacterial Common Antigen (ECA), which is an attractive target for the development of universal acting immunotherapies. We describe here the first chemical synthesis of ECA derived oligosaccharides for the development of such therapies. A number of synthetic challenges had to be addressed including the development of concise synthetic procedures for unusual monosaccharides, the selection of appropriate orthogonal protecting groups, the development of stereoselective glycosylation protocols, appropriate timing for the introduction of carboxylic acids of ManpNAcA moieties and conditions for the reduction of multiple azido moieties. The synthetic compounds were employed to uncover immuno-dominant moieties of ECA. Furthermore, a mAb was developed that binds to ECA and can selectively recognize a wide range of intact Enterobacteriaceae.